三生國健(688336.SH)：選取Verseau的VSIG-4靶點抗體作為腫瘤免疫合作領域的第二個巨噬細胞檢查點調節劑
格隆匯 12 月 14日丨三生國健(688336.SH)公佈，近日，公司與VerseauTherapeutics, Inc. (“Verseau”)宣佈，根據2019年雙方簽署的研發和商業化治療多種癌症的創新單克隆抗體的合作協議，選取VSIG-4靶點的單克隆抗體作為授權產品。該產品為雙方根據合作協議選取的第二個授權產品，第一個授權產品為Verseau於2019年11月18日向公司授權的免疫治療新型靶向PSGL-1單抗藥物VTX-0811。
VSIG-4是一種B7家族I類受體，在腫瘤相關巨噬細胞及樹突狀細胞上高表達。抗VSIG-4抗體將巨噬細胞及樹突狀細胞重新編程為促炎狀態，激活T細胞並吸引其他免疫細胞協同產生強大的抗腫瘤效應。患者來源的原發性腫瘤數據表明，在對PD-1有響應和無響應的腫瘤樣本中，Verseau的VSIG-4抗體表現出比目前免疫療法更強的炎症反應。VSIG-4是巨噬細胞檢查點調節劑管線中第二個進入開發階段的靶點。Verseau的巨噬細胞檢查點調節劑能夠根據疾病情況將巨噬細胞重新編程，使其更具致炎症性或耐受性。
公告顯示，Verseau是一家致力於腫瘤免疫療法的生物製藥企業，其擁有專利的藥物研發平台專注於開發全新的巨噬細胞檢查點調節劑(MCM)，用於癌症、免疫和炎症等多種類疾病的治療。Verseau 已利用其獨有的全人源轉化醫學系統確定了新的靶點，開發了在疾病中使巨噬細胞在免疫激活劑和沉默劑之間相互轉換的療法，並已驗證了適用於包括使用單抗在內的不同治療方式的20餘個靶點。
通過與Verseau的合作，公司步入了免疫腫瘤學領域的創新前沿，創新產品管線進一步豐富，同時一定程度地分攤了研發風險、縮短研發進程、共享知識產權與保障研發成果。公司持續踐行外部項目引進來、內部項目走出去的基本原則，努力引進國際領先、國內稀缺且臨牀需求高的藥物，來滿足未被滿足的臨牀需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
